Serrapeptase has been used widely in clinical practice in Japan and Europe for decades. Dr. Hans Nieper, a legendary medical doctor known for his extensive use of proteolytic enzymes, named it the "Miracle Enzyme" because of its unique abilities. Serrapeptase is made by the bacteria Serratia E15 found in the digestive tract of silkworms, which harness the serrapeptase enzyme to break down food and the walls of their silk cocoons as they emerge in their moth state.
Proteolytic enzymes function in the body to digest and break down proteins into their amino acid components. When taken as supplements away from meals, these enzymes enter the bloodstream and are available to facilitate chemical reactions throughout the body.1 They work in part by helping to support a healthy inflammatory response and by modulating the immune system. Serrapeptase may facilitate a more balanced release of bradykinin (presumably downplaying bradykinin receptor B1 activity).2, 3
In terms of strength, serrapeptase recently demonstrated a greater ability to promote a balanced inflammatory response compared with two powerful proteolytic enzymes secreted by the human pancreas, chymotrypsin and trypsin.4
Serrapeptase has been used for years in Japan for supporting healthy sinus function. Studies thus far suggest that serrapeptase is a promising, safe, and useful supplement to help support the immune system and promote favorable viscosity of nasal mucus.5, 6 In one controlled and randomized open-label study, researchers observed the effects of 30 mg/day (equivalent to ~ 60,000 units of activity) of serrapeptase on the sputum of 29 individuals. After 4 weeks, those taking serrapeptase had significantly less morning sputum, and it was thinner and less elastic in nature compared to those taking placebo. The serrapeptase group also had fewer neutrophils in their sputum, signifying a more balanced immune response.7
- Tachibana, M., et al., A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica, 1984. 3(8): p. 526-30.
- Mecikoglu, M., et al., The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am, 2006. 88(6): p. 1208-14.
- Mazzone, A., et al., Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res, 1990. 18(5): p. 379-88.
- Viswanatha Swamy, A.H. and P.A. Patil, Effect of some clinically used proteolytic enzymes on inflammation in rats. Indian J Pharm Sci, 2008. 70(1): p. 114-7.
- Majima, Y., et al., Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am Rev Respir Dis, 1990. 141(1): p. 79-83.
- Majima, Y., et al., The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus. Arch Otorhinolaryngol, 1988. 244(6): p. 355-9.
- Nakamura, S., et al., Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology, 2003. 8(3): p. 316-20.
*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.